Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine

Psychopharmacology

Volumn 231, Issue 20, 2014, Pages 4081-4082

  Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO SERINE; ESKETAMINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SERINE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER;

AMINO ACID BLOOD LEVEL; ANTIDEPRESSANT ACTIVITY; BIPOLAR DISORDER; DEPRESSION; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; HUMAN; LETTER; MAJOR DEPRESSION; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PREDICTIVE VALUE; SCHIZOPHRENIA; SINGLE DRUG DOSE; TREATMENT RESISTANT DEPRESSION; ANTAGONISTS AND INHIBITORS; BLOOD; DEPRESSIVE DISORDER; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; SERINE; TREATMENT OUTCOME;

EID: 84919372680     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3735-7     Document Type: Letter

References (14)

1. Hashimoto K (2009) Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61:105-123
2. Hashimoto K (2014a) R-Stereoisomer of ketamine as alternative of ketamine for treatment-resistant major depression. Clin Psychopharmacol Neurosci 12:72-73
3. Hashimoto K (2014b) Targeting of NMDA receptors in the new treatment of schizophrenia. Expert Opin Ther Targets 18:1049-1063
4. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M (2003) Decreased serum levels of D-serine in patients with schizophrenia. Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60:572-576
5. Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 263:367-377
6. Hashimoto K, Sawa A, Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310-1316
7. Hirabayashi Y, Furuya S (2008) Roles of L-serine and sphingolipid synthesis in brain development and neuronal survival. Prog Lipid Res 47:188-203
8. Krystal JH, Sanacora G, Duman RS (2013) Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73:1133-1141
9. Maekawa T, Ohnishi T, Hashimoto K, Watanabe A, Iwayama Y, Ohba H, Hattori E, Yamada K, Yoshikawa T (2010) Analyses of mechanism for mouse strain-dependent prepulse inhibition point to a role of Shmt1 (SHMT1) in mice and schizophrenia. J Neurochem 115: 1374-1385
10. Moaddel R, Luckenbaugh DA, Xie Y, Villasenor A, Brutsche NE, Machado-Vieira R, Ramamoorthy A, Lorenzo MP, Carcia A, Bernier M, Torjman MC, Barbas C, Zarate CA, Wainer JW (2014) D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with major depressive disorder. Psychopharmacology in press
11. Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Takao H, Toyota T, Minabe Y, Nakamura K, Shimizu E, Itokawa M, Mori N, Iyo M, Yoshikawa T (2005) Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry 57:1493-1503
12. Yang C, Hashimoto K (2014) Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology 231:2041-2042
13. Zarate CA Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SLV, Ramamoorthy A, Moaddel R, Wainer IW (2012) Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72:331-338
14. Zhang JC, Li SX, Hashimoto K (2014) R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 116:137-141